TGF-β also has antiproliferative effects and is associated with good outcomes in ER+ breast cancer cohorts (32), suggesting that it could mechanistically link lower proliferation rates with immunosuppression and represent a rational drug combination with immune checkpoint targeting (33). This evidence concerns the gene TGFB1 and breast cancer.